Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CardioComm Solutions's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 148.28.
CardioComm Solutions's Days Inventory for the
three
months ended in Dec. 2025 was 63.88.
CardioComm Solutions's Days Payable for the
three
months ended in Dec. 2025 was 109.5.
Therefore, CardioComm Solutions's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 102.66.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
CardioComm Solutions Cash Conversion Cycle Related Terms
CardioComm Solutions Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for CardioComm Solutions's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EKG vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, CardioComm Solutions's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CardioComm Solutions Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CardioComm Solutions's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where CardioComm Solutions's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
CardioComm Solutions's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CardioComm Solutions (TSXV:EKG) has a Cash Conversion Cycle of 102.66 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CardioComm Solutions and its competitors.
Is CardioComm Solutions' Cash Conversion Cycle too high?
CardioComm Solutions' current Cash Conversion Cycle is 102.66. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.83. CardioComm Solutions' value of 102.66 is 475.8% above this industry median.
How does CardioComm Solutions' Cash Conversion Cycle compare to VEEV and BTSG?
CardioComm Solutions' Cash Conversion Cycle of 102.66 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.83. CardioComm Solutions' value of 102.66 is 475.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.83, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CardioComm Solutions's current Cash Conversion Cycle of 102.66 is 475.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CardioComm Solutions and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CardioComm Solutions's current Cash Conversion Cycle is 102.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CardioComm Solutions stock overvalued right now?
CardioComm Solutions (TSXV:EKG) has a current Cash Conversion Cycle of 102.66. The current Cash Conversion Cycle is 102.66 and 475.8% above the Healthcare Providers & Services industry median of 17.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For CardioComm Solutions (TSXV:EKG), the current Cash Conversion Cycle is 102.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CardioComm Solutions Inc develops software, hardware and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The Company has one operating segment, which involves the development of software and the sale of ECG recording equipment and ECG reading services for the cardiology field. Substantially all the Company's operations, assets, and employees are in Canada. Revenue is earned in Canada and the United States. Its products are GEMS Sirona, GEMS WIN, Trident Pro 40L, HeartCheck CardiBeat - Mobile ECG Device, HeartCheck SMART Monitoring, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EKG has been successfully added to your 
